A Phase 3 interventional study of delandistrogene moxeparvovec and placebo in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 42 sites in 9 countries. Open to male participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 3, and was the 20th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 2+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States, Belgium, Germany and 6 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in United States
Men only
By country, each count listing its studies:
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 7 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 7 · Phase 4 1
First in 2009; this study’s year is marked. 1 started in 2021.
This study's enrollment of 126 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 24 across the 25 interventional studies, 400 across the 2 observational. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
2 of the studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07542314Sarepta Therapeutics, Inc.Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study. The participants who are randomized to the placebo arm will have an opportunity for treatment with gene transfer therapy at the beginning of the second year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion or exclusion criteria could apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1. Then, participants will receive a single IV infusion of matching placebo at Year 2.
Genetic: delandistrogene moxeparvovec · Genetic: placebo
Participants will receive matching placebo IV infusion on Day 1. Then, participants will have the opportunity to receive a single IV infusion of delandistrogene moxeparvovec at Year 2.
Genetic: delandistrogene moxeparvovec · Genetic: placebo
Single IV infusion of delandistrogene moxeparvovec.
Also known as: SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS
Single IV infusion of matching placebo.
Part 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52
The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.
Time frame: Baseline, Week 52 (Part 1)
Part 1: Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by Western Blot Adjusted by Muscle Content
Quantity of delandistrogene moxeparvovec dystrophin protein levels (in muscle biopsy samples) were determined by Western blot at Part 1, Week 12. For this endpoint, 2 blocks of tissues were analyzed by Western blot, each with 2 technical replicates to determine the delandistrogene moxeparvovec dystrophin protein level (percent control). The block average value from 2 technical replicates was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for the analysis. Dystrophin protein was measured and then adjusted based on the percentage of muscle content in the biopsy sample. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.
Time frame: Week 12
Part 1: Change From Baseline in Time to Rise From the Floor at Week 52
The time to rise from the floor test quantifies the time required for the participant to stand in an upright position with arms by sides, starting from the supine position with arms by sides. Data are presented for the change from baseline to Week 52 in the time taken (in seconds) to rise from the floor.
Time frame: Baseline, Week 52 (Part 1)
Part 1: Change From Baseline in Time to Complete 10 Meter Walk/Run (10MWR) at Week 52
The timed 10MWR quantifies the time required for the participant to run or walk 10 meters (on a straight walkway) from a standing position. Data are presented for change from baseline to Week 52 in the time (in seconds) taken to complete the 10MWR.
Time frame: Baseline, Week 52 (Part 1)
Part 1: Change From Baseline in Time to Complete 100 Meter Walk/Run (100MWR) at Week 52
The timed 100MWR quantifies the time required for the participant to run or walk 100 meters (on a straight walkway) from a standing position. Data are presented for change from baseline to Week 52 in the time (in seconds) taken to complete the 100MWR.
Time frame: Baseline, Week 52 (Part 1)
Part 1: Change From Baseline in the Timed Stair Ascend 4 Steps Test at Week 52
The timed stair ascend 4 steps test quantifies the time required for the participant to ascend 4 standard steps (each step was 6 inches in height). Data presented is the change from baseline to Week 52 in the time (in seconds) to ascend 4 steps.
Time frame: Baseline, Week 52 (Part 1)
Part 1: Change From Baseline in Stride Velocity 95th Centile (SV95C) at Week 52
Each participant was provided with wearable devices to collect data on stride velocity. Participants wore a device on each ankle. SV95C data was derived based on stride velocity. Data are presented for change from baseline to Week 52 in SV95C.
Time frame: Baseline, Week 52 (Part 1)
Part 1: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Score in Mobility to Week 52
PROMIS is a family of instruments developed and validated to assess health-related quality of life, including mobility. Mobility function scores ranged from 1 (worst mobility function) to 5 (best mobility function), where higher scores indicate a better clinical outcome.
Time frame: Baseline, Week 52 (Part 1)
Part 1: Change From Baseline in PROMIS Score in Upper Extremity Function to Week 52
PROMIS is a family of instruments developed and validated to assess health-related quality of life, including upper extremity function. Upper extremity function scores ranged from 1 (not able to do so \[worst upper extremity function\]) to 5 (no trouble \[best upper extremity function\]), where higher scores indicate a better clinical outcome.
Time frame: Baseline, Week 52 (Part 1)
Part 1: Number of Skills Gained or Improved at Week 52 as Measured by the NSAA
The NSAA is a clinician-administered scale that rates performance on various functional activities. As measured by the NSAA, data was collected for the number of skills gained (the average item score was 0 at Baseline and \> 0 at Part 1 Week 52) or improved (the average item score at Baseline was \> 0 but less than the average item score at Part 1 Week 52). As pre-specified, data are presented for the combined number of skills gained or improved at Week 52.
Time frame: Week 52 (Part 1)
Parts 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
TEAEs were defined as an adverse event (AE) that emerged during treatment, having been absent pre-treatment, or worsened relative to the pretreatment state. SAEs were defined as any adverse event that resulted in death, was life threatening, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or was an important medical event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to 104 weeks
Parts 1 and 2: Number of Participants With Adverse Events of Special Interest (AESI)
AESIs were defined as adverse events (AEs) of special interest, based on pre-specified criteria and pertain to categories labeled hepatotoxicity, immune-mediated myositis, thrombotic microangiopathy (TMA), hypersensitivity, thrombocytopenia, rhabdomyolysis, and troponin I elevations. The data represent the number of participants who experienced an event within the specified AESI category as observed by the principal investigator (PI), after adjudication. Per prespecified analysis, AESI data were only collected based on the specified AESI categories. A Summary of all SAEs and nonserious AEs ("Other"), regardless of causality and regardless of the AESI category, is located in the "Reported Adverse Events" section.
Time frame: Up to 104 weeks
| Milestone | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Started | 63 | 62 |
| Received at least 1 dose of study drug in part 1 | 63 | 62 |
| Completed | 63 | 62 |
| Not completed | 0 | 0 |
| Milestone | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Started | 63 | 60 |
| Received at least 1 dose of study drug in part 2 | 62 | 60 |
| Completed | 63 | 59 |
| Not completed | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.
| scores on a scale | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52 | 2.57 ± 0.39 | 1.92 ± 0.39 |
Quantity of delandistrogene moxeparvovec dystrophin protein levels (in muscle biopsy samples) were determined by Western blot at Part 1, Week 12. For this endpoint, 2 blocks of tissues were analyzed by Western blot, each with 2 technical replicates to determine the delandistrogene moxeparvovec dystrophin protein level (percent control). The block average value from 2 technical replicates was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for the analysis. Dystrophin protein was measured and then adjusted based on the percentage of muscle content in the biopsy sample. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.
| Percent control | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by Western Blot Adjusted by Muscle Content | 34.29 ± 41.04 | 0.00 ± 0.00 |
The time to rise from the floor test quantifies the time required for the participant to stand in an upright position with arms by sides, starting from the supine position with arms by sides. Data are presented for the change from baseline to Week 52 in the time taken (in seconds) to rise from the floor.
| Seconds | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Change From Baseline in Time to Rise From the Floor at Week 52 | -0.27 ± 0.15 | 0.37 ± 0.15 |
The timed 10MWR quantifies the time required for the participant to run or walk 10 meters (on a straight walkway) from a standing position. Data are presented for change from baseline to Week 52 in the time (in seconds) taken to complete the 10MWR.
| Seconds | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Change From Baseline in Time to Complete 10 Meter Walk/Run (10MWR) at Week 52 | -0.34 ± 0.10 | 0.08 ± 0.10 |
The timed 100MWR quantifies the time required for the participant to run or walk 100 meters (on a straight walkway) from a standing position. Data are presented for change from baseline to Week 52 in the time (in seconds) taken to complete the 100MWR.
| Seconds | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Change From Baseline in Time to Complete 100 Meter Walk/Run (100MWR) at Week 52 | -6.57 ± 1.76 | -3.28 ± 1.80 |
The timed stair ascend 4 steps test quantifies the time required for the participant to ascend 4 standard steps (each step was 6 inches in height). Data presented is the change from baseline to Week 52 in the time (in seconds) to ascend 4 steps.
| Seconds | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Change From Baseline in the Timed Stair Ascend 4 Steps Test at Week 52 | -0.44 ± 0.12 | -0.08 ± 0.13 |
Each participant was provided with wearable devices to collect data on stride velocity. Participants wore a device on each ankle. SV95C data was derived based on stride velocity. Data are presented for change from baseline to Week 52 in SV95C.
| meters (m)/second (s) | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Change From Baseline in Stride Velocity 95th Centile (SV95C) at Week 52 | 0.06 ± 0.03 | -0.03 ± 0.03 |
PROMIS is a family of instruments developed and validated to assess health-related quality of life, including mobility. Mobility function scores ranged from 1 (worst mobility function) to 5 (best mobility function), where higher scores indicate a better clinical outcome.
| Scores on a scale | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Score in Mobility to Week 52 | 0.05 ± 0.05 | -0.01 ± 0.05 |
PROMIS is a family of instruments developed and validated to assess health-related quality of life, including upper extremity function. Upper extremity function scores ranged from 1 (not able to do so \[worst upper extremity function\]) to 5 (no trouble \[best upper extremity function\]), where higher scores indicate a better clinical outcome.
| scores on a scale | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Change From Baseline in PROMIS Score in Upper Extremity Function to Week 52 | 0.19 ± 0.07 | 0.23 ± 0.07 |
The NSAA is a clinician-administered scale that rates performance on various functional activities. As measured by the NSAA, data was collected for the number of skills gained (the average item score was 0 at Baseline and \> 0 at Part 1 Week 52) or improved (the average item score at Baseline was \> 0 but less than the average item score at Part 1 Week 52). As pre-specified, data are presented for the combined number of skills gained or improved at Week 52.
| number of skills | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec |
|---|---|---|
| Part 1: Number of Skills Gained or Improved at Week 52 as Measured by the NSAA | 4.18 ± 0.31 | 3.99 ± 0.31 |
TEAEs were defined as an adverse event (AE) that emerged during treatment, having been absent pre-treatment, or worsened relative to the pretreatment state. SAEs were defined as any adverse event that resulted in death, was life threatening, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or was an important medical event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Part 1: Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2 | Part 1: Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2 | Part 2: Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2 | Part 2: Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2 |
|---|---|---|---|---|
| TEAEs | 62 | 57 | 53 | 56 |
| SAEs | 14 | 5 | 5 | 8 |
AESIs were defined as adverse events (AEs) of special interest, based on pre-specified criteria and pertain to categories labeled hepatotoxicity, immune-mediated myositis, thrombotic microangiopathy (TMA), hypersensitivity, thrombocytopenia, rhabdomyolysis, and troponin I elevations. The data represent the number of participants who experienced an event within the specified AESI category as observed by the principal investigator (PI), after adjudication. Per prespecified analysis, AESI data were only collected based on the specified AESI categories. A Summary of all SAEs and nonserious AEs ("Other"), regardless of causality and regardless of the AESI category, is located in the "Reported Adverse Events" section.
| Participants | Part 1: Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2 | Part 1: Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2 | Part 2: Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2 | Part 2: Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2 |
|---|---|---|---|---|
| Hepatotoxicity | 12 | 0 | 0 | 14 |
| Immune-mediated Myositis | 0 | 0 | 0 | 0 |
| TMA | 0 | 0 | 0 | 0 |
| Hypersensitivity | 1 | 0 | 1 | 0 |
| Thrombocytopenia | 2 | 0 | 1 | 0 |
| Rhabdomyolysis | 1 | 1 | 0 | 0 |
| Troponin I elevations | 2 | 1 | 14 | 8 |
Collected over Up to approximately 104 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Delandistrogene Moxeparvovec | 0/63 (0%) | 14/63 (22.2%) | 62/63 (98.4%) |
| Part 1: Placebo | 0/62 (0%) | 5/62 (8.1%) | 57/62 (91.9%) |
| Part 2: Placebo | 0/63 (0%) | 5/63 (7.9%) | 52/63 (82.5%) |
| Part 2: Delandistrogene Moxeparvovec | 0/60 (0%) | 8/60 (13.3%) | 55/60 (91.7%) |
| Event | Part 1: Delandistrogene Moxeparvovec | Part 1: Placebo | Part 2: Placebo | Part 2: Delandistrogene Moxeparvovec |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 2/63 | 1/62 | 0/63 | 2/60 |
| HepatotoxicityHepatobiliary disorders | 1/63 | 0/62 | 0/63 | 2/60 |
| PyrexiaGeneral disorders | 1/63 | 1/62 | 0/63 | 2/60 |
| COVID-19Infections and infestations | 2/63 | 1/62 | 0/63 | 0/60 |
| Gamma-glutamyltransferase increasedInvestigations | 1/63 | 0/62 | 0/63 | 1/60 |
| Hepatic enzyme increasedInvestigations | 1/63 | 0/62 | 0/63 | 1/60 |
| Liver injuryHepatobiliary disorders | 1/63 | 0/62 | 0/63 | 1/60 |
| GastroenteritisInfections and infestations | 0/63 | 0/62 | 0/63 | 1/60 |
| Anal abscessInfections and infestations | 0/63 | 1/62 | 0/63 | 0/60 |
| InfluenzaInfections and infestations | 0/63 | 1/62 | 0/63 | 0/60 |
| Event | Part 1: Delandistrogene Moxeparvovec | Part 1: Placebo | Part 2: Placebo | Part 2: Delandistrogene Moxeparvovec |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 39/63 | 11/62 | 9/63 | 43/60 |
| NauseaGastrointestinal disorders | 24/63 | 8/62 | 5/63 | 23/60 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/63 | 19/62 | 12/63 | 20/60 |
| Decreased appetiteMetabolism and nutrition disorders | 20/63 | 3/62 | 1/63 | 15/60 |
| PyrexiaGeneral disorders | 19/63 | 14/62 | 5/63 | 12/60 |
| Glutamate dehydrogenase increasedInvestigations | 18/63 | 2/62 | 1/63 | 12/60 |
| Upper respiratory tract infectionInfections and infestations | 13/63 | 17/62 | 10/63 | 13/60 |
| COVID-19Infections and infestations | 15/63 | 10/62 | 6/63 | 6/60 |
| DiarrhoeaGastrointestinal disorders | 6/63 | 13/62 | 0/63 | 8/60 |
| Gamma-glutamyltransferase increasedInvestigations | 5/63 | 0/62 | 2/63 | 12/60 |
Measured in the Modified Intent-to-Treat (mITT) Population, which included all randomized participants who received study treatment, with treatment group designated according to randomization.
| Age, Continuous(years) | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| Mean | 5.98 ± 1.06 | 6.08 ± 1.05 | 6.03 ± 1.05 |
| Sex: Female, Male(Participants) | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 63 | 62 | 125 |
| Ethnicity (NIH/OMB)(Participants) | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 8 | 23 |
| Not Hispanic or Latino | 47 | 53 | 100 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Delandistrogene Moxeparvovec Followed by Placebo | Placebo Followed by Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 8 | 11 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black of African American | 0 | 2 | 2 |
| White | 49 | 46 | 95 |
| More than One Race | 1 | 0 | 1 |
| Other or Not Reported | 5 | 3 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2021 to primary completion in Oct 2023, 23 months.
Results were first posted in Dec 2024, 1 year 2 months after primary completion.
Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →